Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announced today that it has entered into a partnership agreement with Hospira regarding the supply of LISA-TRACKER’s CE-marked infliximab monitoring kit.
Visiun, Inc., the leader in performance analytics for the laboratory, announced today the release of a utilization management reporting system for laboratories nationwide. This new solution will help laboratories identify opportunities to eliminate unnecessary testing. In an environment of decreasing reimbursements, test utilization represents one of the greatest opportunities for laboratories to improve financial performance.
In this month’s release, find new embargoed research about obese people attaining normal weight; circumcision’s link to health insurance; health care providers’ biases based on sexual orientation.
In 2012 Maine Biotechnology Services entered into a partnership with Drs. Mark Heise and Kristen Long of the University of North Carolina Medical School, with the objective of developing monoclonal antibodies to support ongoing research efforts to advance adequate vaccine and rapid detection methods for Chikungunya virus, an emerging global infection. MBS is announcing the release of three monoclonal antibodies resulting from that partnership. The 181/25 vaccine strain of CHKV was used as the immunogen and all three antibodies detect active strains of Chikungunya virus by ELISA. In addition to recognizing the immunizing vaccine strain 181/25 by ELISA, these clones also to the CHIKV strain originating in Sri Lanka. Further ELISA data indicates that the antibodies do not cross-react with other alphaviruses including Mayaro, Ross River and O’nyong-nyong viruses. Applications for these antibodies include the detection of active virus either in circulation or in mosquito carriers.MAB243P
MBS has added a new norovirus antibody to a diagnostic panel that now includes seven monoclonal antibodies. MAB242P, the most recently developed antibody, is the first MBS antibody to recognize both GI and GII strains of norovirus. MAB242P complements our previous offering of antibodies that were exclusive for either GI or GII strains of the virus. With this complete panel, MBS now meets customers’ broad and diverse diagnostic goals.
Maine Biotechnology Services is announcing the addition of Bacterial Recombinant Protein Expression and Purification services to compliment our complete antibody service offering, adding value and efficiency to custom antibody development with MBS.
Medical Electronic Systems (MES) today announced the worldwide release of the SQA-Vision, the company’s new automated sperm quality analyzer. The SQA-Vision was developed based on 10 years of market feedback and is positioned to augment the company’s line of SQA-V and QwikCheck™ semen analyzers with a top of the line solution. Some of the enhanced features of the SQA-Vision include a high definition touch screen interface, expanded testing options and state of the art digital magnification with ‘Click-to-Mark’ interface.
Precision Die Cutting, with operations in Chino, California and in Singapore, has become the Industry leader in providing support to OEM companies the Lateral Flow/ IVD market. They have a 10+ year history providing their industry approved "KN2211 adhesive" laminated to various plastic backings. They also supply custom printed cover tapes and other custom converted components.
As one of the premiere companies in the medical device industry, Mindray in 1997 ventured into and found success in the In-Vitro Diagnostic business. After more than 20 years of dedication, Mindray today is one step closer to offering end-users a total solution of Hematology.
Streck introduces CD-Chex CD103™ Plus, the only commercially available flow cytometry control that includes CD103, CD30, CD38, CD56, CD138, and Cytoplasmic Lambda in a single control, and the only control on the market to provide reference values for CD138.
Streck has introduced a new flow cytometry control, CD-Chex TdT Plus. It is the only commercially available flow cytometry control assayed for TdT, CD1a, CD34 and cCD3 in a single control.
Pope Francis’ encyclical on climate change marked an historic event, but as American University Philosophy and Religion Associate Prof. Evan Berry points out, Christianity’s ties with ecology are far from new. Berry's new book explores the religious roots of environmentalism.
Beckman Coulter Diagnostics received US Food and Drug Administration (FDA) 510(k) clearance for its UniCel DxH v3.0 software, which supports automated connectivity of the diagnostic use. The clearance enables laboratories to connect up to three DxH 800 analyzers to a DxH Slidemaker Stainer to create a customized, scalable workflow solution.
Beckman Coulter Diagnostics announces the publication of research results in the Clinical Biochemistry journal that identifies the precise magnitude of change in cardiac troponin required for early diagnosis of a heart attack (myocardial infarction, or MI), utilizing its Access AccuTnI+3 troponin I blood test. Beckman Coulter’s troponin-I assay has been clinically proven through a large, multi-center study and is the only troponin assay currently cleared by the U.S. Food and Drug Administration (FDA) that is directly aligned with the agency’s October 2010 guidance to manufacturers of troponin tests.
Beckman Coulter, an indirect wholly-owned subsidiary of Danaher Corporation (NYSE:DHR), announced today that it has entered into a definitive agreement to purchase the clinical microbiology business of Siemens Healthcare Diagnostics.
Fluid systems in medical devices are becoming compact and more sophisticated. The traditionally used syringe pumps seem no longer able to keep up with the new requirements in terms of size, cost and performance. Valve-less piston pumps that combine the benefits of syringe pumps with lower cost and higher performance, could be the solution of the future. Diener Precision Pumps will present a live demo of valve-less piston pumps at the AACC Annual Meeting & Clinical Lap Expo in Atlanta, Georgia/USA in July.
Every application is different and has its individual requirements. This is why Diener Precision Pumps, the Swiss quality manufacturer of gear pumps and piston pumps, designs and produces also the manifolds exactly to individual specifications.
The DRG:Hybrid-XL® will be showcased as the centerpiece of DRG International’s display at the 2015 AACC conference in Atlanta, Georgia. The AACC, held from July 27-30, is the premiere conference of its type, welcoming all the leaders in the clinical chemistry field year after year. The DRG:Hybrid-XL® desktop analyzer is now available in the market worldwide and has revolutionized automation for laboratories. It is suitable for small to medium-sized laboratories, providing diagnostic services to research facilities in hospitals, clinics and large medical practices.
The DRG® 25-OH Vitamin D (total) ELISA, an enzyme immunoassay for the measurement of total 25-OH Vitamin D (Vitamin D2 and Vitamin D3) in both serum and plasma, will be a highlight of the 2015 American Association for Clinical Chemistry (AACC) Conference on July 27-30 in Atlanta, Georgia.
DRG International, a leading international medical diagnostic company, will showcase its DRG® Aldosterone ELISA Kit at the 2015 AACC in Atlanta, Georgia on July 27-30. The DRG International Aldosterone ELISA is for measurement of Aldosterone in serum, plasma, and urine.
DRG International’s Renin (Active) ELISA for testing of active Renin in human EDTA plasma will be on display at the AACC’s 2015 show Atlanta, Georgia on July 27-30. The DRG® Renin active ELISA test is accurate in testing for certain types of hypertension and has been utilized by labs world-wide.
Total Lab Care (TLC), an ELITechGroup specialized consultant provider for Physician Office Laboratories (POLs) announces that its Laboratory Essentials Course has been approved for 3.5 hours of P.A.C.E. continuing education credits. Course participants will learn or refresh their memory on the basics of the clinical laboratory in a self‐paced environment. This web‐based interactive training program, comprised of 10 individual lessons, reviews CLIA rules and regulations and laboratory operations from pre‐analytical to post‐analytical processes including laboratory testing requirements (i.e. pipetting, safety, equipment operation, etc.).
EMD Millipore Introduces New High-Performance Water Purification Systems with 24/7 Real-Time Monitoring and Remote Control • New AFS® 40E / 80E / 120E and 150E systems fulfill pure water needs for one or several high-throughput clinical analyzers.
Kathy Holland, MD is the Director of Operations and Medical Director of Equitech Enterprises which supplies custom normal and disease state blood collections. Dr. Holland has extensive experience in the human blood collection field. From being a small enterprise, she has increased its donor base to include a wide range of age, ethnicity, and disease state. All collections receive viral screening including HIV, Hepatitis B&C, Syphilis, and other selected markers. All donors receive, and are qualified by, a fully comprehensive three page Donor Health Questionnaire in which data and demographics information is given on request. They provide custom specimen collections or bulk quantities ranging from a single unit to hundreds of liters. Equitech Enterprises, Inc. is FDA Approved, and IRB Certified.
KNF Neuberger, Inc. announces an extension to the line of brushless DC powered NFB boxer pumps with the addition of two compact, powerful models. The new NFB 5 and NFB 25 feature low pulsation, gentle transfer of liquids from 5 – 300 mL/min per head, and cost savings thanks to efficient design and long product life.
MBS MAB230P, monoclonal antibody to the polyhistidine (HIS) tag has been incorporated into the second generation Forte Bio Anti-HIS biosensors for rapid quantitative measurement of HIS tagged proteins. MAB230P was selected by ForteBio after demonstrating high specificity and excellent sensitivity, detecting HIS tagged proteins in nanogram quantities. The antibody is broadly reactive, recognizing HIS tags of 4X or greater, engineered at either the N- or C-terminus of the protein. The internal development and production of MAB230P allows MBS to maintain the highest quality standards and the ability to offer the lowest price in the marketplace.
Activity and outcome scores like DAS, DAS28, SDAI or CDAI, Larsen Score, etc. are commonly used but are time consuming and not practical in the early phase of rheumatoid arthritis (RA). Moreover, no validated or accepted uniform criteria exist to classify individuals with early RA in terms of disease progression and severity. Even if CCP has been added to the 2010 ACR criteria for diagnostic purposes, its usefulness as a marker for disease activity and progression is still under discussion. But this information is exactly what is needed to choose the appropriate therapy because not all early disease patients are candidates for DMARD or biological therapy, mainly due to toxicity reasons. Aggressive therapy is recommended only for those who are at risk of rapid joint destruction.
Seralite® - FLC is a rapid diagnostic device for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum as an aid to the diagnosis and management of multiple myeloma. The assay provides an accurate picture of disease status in 10 minutes. Using a simple to use, portable, rapid test, clinicians are able to monitor patients in “real time” supporting faster decision making
Yantai Addcare Bio-Tech Limited Company is a high-tech enterprise engaged in the development, production and sales of fully automated liquid handling systems, immunoassay workstations and related products. We are currently the only manufacturer in China holding independent intellectual property rights in this product segment.
Background
Immunofluorescence Assays (IFA) used for screening of autoimmune diseases have a number of challenges. When performed manually, IFA is laborious, subjective and poorly standardized. With the advent of multiplex technologies in early-2000, the autoimmune community thought it had found a solution, until it became evident that multiplex technologies had limitations, which made them poor candidates for antinuclear antibody screening (ANA). Today, there are 30 to 50 clinically significant autoantibodies outside of the HEp-2 cell, which currently have no method for screening.1
Every baby born that enters this world, arrives with an umbilical cord in tow. For those babies born addicted to drugs, that umbilical cord is now a key connection—a hard to hide clue—for identifying what drugs are coursing through a newborn’s veins. The drug(s) detected will help physicians determine the best treatment and what withdrawal symptoms to expect.
“There is no cure for HHT, yet if we can find new genetic modifiers or new genes, then we can potentially find novel therapeutics to treat these patients,” explains an enthusiastic Whitney Wooderchak-Donahue, PhD, a researcher with the University of Utah and ARUP Laboratories. Last week, she received the 2015 Young Scholar Research Grant ($30,000) for her research proposal that involves focusing on patients’ transcripts (the RNA in the cell) via their blood samples to identify genetic modifiers in Hereditary Hemorrhagic Telangiectasia (HHT).
Asahi Kasei Fibers has begun commercial production and supply of NanoAct™ cellulose nanobeads, and is now accelerating the development of lateral flow immunoassays in Japan and worldwide.
Remember when the doctor came to your house? Well, your grandmother does. Now doctors are coming to the workplace. Not only is it convenient for employees—saving time and keeping them nearby—but, executives are seeing company savings in a time of rising healthcare costs.
As thousands turn out this spring to run and walk in memory of loved ones lost to breast cancer, behind-the-scene researchers are running a race of a different kind to help physicians treat their cancer patients. It is a race to acquire genetic knowledge, and success is dependent on collaborations and expertise from researchers worldwide.
Beckman Coulter Diagnostics has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Access 25(OH) Vitamin D Total assay. Offering state-of-the-art performance, the new assay is an important addition to the company’s bone metabolism assay menu and is available for use on its Access 2 and UniCel DxI series of immunoassay systems.
DRG International, a leading international medical diagnostic company, will showcase the NEW DRG® Hepcidin 25 (bioactive) HS (High Sensitive) ELISA Kit (EIA-5782) at the 2015 AACC in Atlanta, Georgia from July 27-30. As the first of its kind to market, this kit accurately detects bioactive Hepcidin levels as an additional marker to aid in identifying a variety of disorders. In recent years, a large number of publications identify Hepcidin as a factor in regulating the amount of iron in humans. Unbalanced iron level can lead to many common medical conditions including anemia and iron overload disease, and can occur in chronic kidney disease, inflammation, or diabetes mellitus
Following the commercial launch of Seralite® - FLC Abingdon Health is looking to appoint distributors in order to enable as many people as possible affected by multiple myeloma (a cancer arising from plasma cells) to have access to, and benefit from its rapid diagnostic capabilities.
The Lee Company’s new LPG Series Inert Solenoid Pump was designed to offer greater design flexibility and significant cost savings to the medical and scientific industries.
"No swimming" signs have already popped up this summer along coastlines where fecal bacteria have invaded otherwise inviting waters. Some vacationers ignore the signs while others resign themselves to tanning and playing on the beach. But should those avoiding the water be wary of the sand, too? New research in the ACS journal Environmental Science & Technology investigates reasons why the answer could be "yes."
In the U.S. and other industrialized nations, testing for infectious diseases and cancer often requires expensive equipment and highly trained specialists. In countries where resources are limited, performing the same diagnostics is far more challenging. To address this disparity, scientists are developing a portable, low-cost “paper machine” for point-of-care detection of infectious diseases, genetic conditions and cancer. Their report appears in the ACS journal Analytical Chemistry.
This is S&T’s third technology that has successfully gone through the Transition to Practice (TTP) program and into the commercial market. The Network Mapping System (NeMS), developed by Lawrence Livermore National Laboratory, is a software-based tool that tells users what is connected to their network so that they know what needs to be protected.
• Certain electrocardiogram measures helped investigators identify a subgroup of individuals with chronic kidney disease who had substantially elevated risks of dying from heart disease.